CD274 and small cell lung carcinoma: All of these features are encouraging premises for the role of immunotherapy in the treatment of SCLC, and some improvements have been made in the last years since the introduction in clinical practice of agents targeting programmed cell death protein-1 (PD-1) or programmed death-ligand 1 (PD-L1).